BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1550 related articles for article (PubMed ID: 24486412)

  • 21. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions.
    Chae KS; Kang MJ; Lee JH; Ryu BK; Lee MG; Her NG; Ha TK; Han J; Kim YK; Chi SG
    Oncogene; 2011 Mar; 30(10):1213-28. PubMed ID: 21057546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
    Wu L; Zhou J; Zhou W; Huang XF; Chen Q; Wang W; Zhai L; Li S; Tang Z
    Pathol Res Pract; 2021 Apr; 220():153270. PubMed ID: 33640712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
    J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y; Harada M
    Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
    Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
    Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
    Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
    Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
    Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
    Mu H; Yu G; Li H; Wang M; Cui Y; Zhang T; Song T; Liu C
    Cell Oncol (Dordr); 2021 Oct; 44(5):1151-1166. PubMed ID: 34339013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na
    Jiang W; Li G; Li W; Wang P; Xiu P; Jiang X; Liu B; Sun X; Jiang H
    Sci Rep; 2018 Jun; 8(1):9706. PubMed ID: 29946188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop.
    Zheng S; Ni J; Li Y; Lu M; Yao Y; Guo H; Jiao M; Jin T; Zhang H; Yuan A; Wang Z; Yang Y; Chen Z; Wu H; Hu W
    Pharmacol Res; 2021 Jul; 169():105685. PubMed ID: 34022398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ascochlorin inhibits growth factor-induced HIF-1α activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells.
    Jeong JH; Jeong YJ; Cho HJ; Shin JM; Kang JH; Park KK; Park YY; Chung IK; Chang HW; Magae J
    J Cell Biochem; 2012 Apr; 113(4):1302-13. PubMed ID: 22109717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 78.